Evidence map›Paper›PMID 40499538›Full record

ArticleAmerican journal of human genetics2025

Bi-allelic mutations in FASTKD5 are associated with cytochrome c oxidase deficiency and early- to late-onset Leigh syndrome.

Hana Antonicka, Woranontee Weraarpachai, Katherine M Szigety, Robert Kopajtich, James B Gibson, Johan L K Van Hove, Marisa W Friederich, Piervito Lopriore, Christiane Neuhofer, Roxanne A Van Hove and 8 more

Abstract readCase Reports
In one paragraph

Article in American journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hana AntonickaDepartment of Human Genetics, McGill University, Montreal, QC H3A 2B4, Canada; The Neuro, Montreal Neurological Institute, Montreal, QC H3A 2B4, Canada.
Woranontee WeraarpachaiDepartment of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Katherine M SzigetyDivision of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Robert KopajtichInstitute of Neurogenomics, Computational Health Center, Helmholtz Zentrum Munich, Neuherberg, Germany; School of Medicine, Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany.
James B GibsonSection of Metabolic Genetics, Dell Children's Medical Center of Central Texas, Austin, TX, USA; Department of Pediatrics, Dell Medical School at University of Texas at Austin, Austin, TX, USA.
Johan L K Van HoveSection of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado, Aurora, CO 80045, USA; Mitochondrial Laboratory, Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA.
Marisa W FriederichSection of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado, Aurora, CO 80045, USA; Mitochondrial Laboratory, Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA.
Piervito LoprioreNeurological Institute, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Christiane NeuhoferInstitute of Neurogenomics, Computational Health Center, Helmholtz Zentrum Munich, Neuherberg, Germany; School of Medicine, Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany; Institute of Clinical Human Genetics, University Hospital Regensburg, Regensburg, Germany.
Roxanne A Van HoveSection of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado, Aurora, CO 80045, USA.
Michel A ColeDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Richard ReisdorphDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
James T PetersonMitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Katherine J DempseyDivision of Genetics, Department of Pediatrics, Atrium Health Levine Children's Hospital, Charlotte, NC, USA.
Rebecca D GanetzkyDivision of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Michelangelo MancusoNeurological Institute, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Holger ProkischInstitute of Neurogenomics, Computational Health Center, Helmholtz Zentrum Munich, Neuherberg, Germany; School of Medicine, Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany; German Center for Child and Adolescent Health (DZKJ), Partner Site Munich, Munich, Germany.
Eric A ShoubridgeDepartment of Human Genetics, McGill University, Montreal, QC H3A 2B4, Canada; The Neuro, Montreal Neurological Institute, Montreal, QC H3A 2B4, Canada. Electronic address: eric.shoubridge@mcgill.ca.

Funding

The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VAN HOVE, JOHAN L · 2011 to 2023
$17.5M
Fusion Lumos Orbitrap System for Quantitative Proteomics and Metabolomics ApplicationsS10OD028538 · OD · UNIVERSITY OF COLORADO DENVER · PI REISDORPH, NICHOLE A · 2021 to 2021
$1.3M
NIH HHS S10 OD028538NINDS NIH HHS U54 NS078059
6 · The paper itself

Abstract

Using exome sequencing, we identified compound heterozygous variants of unknown significance in FASTKD5, a gene that codes for a mitochondrial protein essential for processing mRNAs at non-canonical cleavage sites in the primary mitochondrial transcript, in three subjects with Leigh syndrome, a progressive neurodegenerative disease characterized by lesions in the brainstem and basal ganglia. Among the three subjects, we identified three missense variants and two frameshift variants leading to a premature stop codon. Analysis of fibroblasts from two subjects showed reduced steady-state levels of FASTKD5 protein by immunoblot, reduced translation of the cytochrome c oxidase subunit 1, impaired assembly of complex IV, and a consequent decrease in cytochrome c oxidase enzymatic activity. The extent of these deficiencies appeared to correlate with the severity of the clinical phenotype. Expression of a wild-type FASTKD5 cDNA, but not cDNAs expressing the missense mutations, rescued all the molecular defects in the subjects' fibroblasts, demonstrating that the alleles are pathogenic. Two of the three identified missense mutations resulted in near complete loss of function, while one was hypomorphic, resulting from impaired protein stability. These cases of mitochondrial disease associated with bi-allelic variants in FASTKD5 add to a growing list of primary genetic mutations causing Leigh syndrome associated with complex IV deficiency.

Indexed as

Cytochrome-c Oxidase DeficiencyLeigh DiseaseMitochondrial ProteinsMutationAdultAge of OnsetAllelesElectron Transport Complex IVFemaleFibroblastsHumansMaleMitochondriaMutation, MissenseElectron Transport Complex IVMitochondrial Proteinscytochrome c oxidase deficiencyFASTKD5Leigh syndromemitochondrial diseasemitochondrial DNAmitochondrial gene expressionmitochondrial translationneurodegenerative diseaseRNA processing

Identifiers

PMID40499538
PMCPMC12256832

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.